From cell production to installation
Following the repurchase of Cillbiotech in 2007, Ipratech has been developing two distinctly different activities that nevertheless remain inherently connected: the production and commercialization of mammalian cells for university laboratories and small pharmaceutical companies (IpraCell), and the installation of equipment for the production of these cells (IpraBio).
Ipratech is attentive to the needs and problems faced by biologists in their daily work, has been responsible for the manufacturing the fully automated continuous (over months) production systems to improve the qualitative and quantitative results of cell cultures, providing innovative yet user-friendly solutions so as to facilitates the research or production of new biologics. The products are the result of 4 years of research on the daily management of cell cultures infused into clean environment. The initial focus and success of Ipratech has been on state-of-the art upstream design of any cell culture process based on fed-batch to perfusion with several proven successes using typical animal cell lines.
Company’s expanding strategy
The company’s expanding strategy for bioprocessing also benefits from the use of Ipratech’s proprietary model for perfusion control with CYTOSYS, coupled to a perfusion device (CYTOPERF) that is either customized in-house or at the customer’s site for application to any cell culture process. Through the CYTOSYS station and its diverse components apace with Iprabio, Ipratech offers a solution for production and control of continuous cells both remotely and “on line”. This particular equipment, unique to its market, is intended for the large pharmaceutical companies that are actually producing the mammalian cells for the purpose of new therapeutic solutions themselves.
From Belgium to Boston
In January of 2013, Ipratech has founded APIcells, Inc. with a strategy to launch its shared technologies to the biopharmaceutical market and a vision to enhance productivity with lower running-costs for cell culture processes. This commercial subsidiary has been established on the outskirts of Boston, Massachusetts and has also introduced an intensive plan of collaboration with UMASS – M2D2 as well as other partners.